Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency

키워드

참고문헌 (94)

1. Bian L, "MRE11-RAD50-NBS1 complex alterations and DNA damage response : implications for cancer treatment", Mol Cancer, 18, pp.169~ (2019)
2. Whelan DR, "Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks", Nat Commun, 9, pp.3882~ (2018)
3. Ghezraoui H, "53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ", Nature, 560, pp.122~127 (2018)
4. Aylon Y, "The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle", EMBO J, 23, pp.4868~4875 (2004)
5. Zhao B, "The molecular basis and disease relevance of non-homologous DNA end joining", Nat Rev Mol Cell Biol, 21, pp.765~781 (2020)
6. Truong LN, "Microhomology-mediated end joining and homologous reco-mbination share the initial end resection step to repair DNA double-strand breaks in mammalian cells", Proc Natl Acad Sci U S A, 110, pp.7720~7725 (2013)
7. Scully R, "DNA double-strand break repair-pathway choice in somatic mammalian cells", Nat Rev Mol Cell Biol, 20, pp.698~714 (2019)
8. Scully R, "In search of the tumour-suppressor functions of BRCA1 and BRCA2", Nature, 408, pp.429~432 (2000)
9. Lim BW, "Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants", J Natl Cancer Inst, 115, pp.181~189 (2023)
10. Ray Chaudhuri A, "Replication fork stability confers chemoresistance in BRCA-deficient cells", Nature, 535, pp.382~387 (2016)
11. San Martin Alonso M, "Untangling the crosstalk between BRCA1 and R-loops during DNA repair", Nucleic Acids Res, 49, pp.4848~4863 (2021)
12. Birkbak NJ, "Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents", Cancer Discov, 2, pp.366~375 (2012)
13. Popova T, "Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1", 2 inactivation, 2012, pp.72, 5454~5462
14. Telli ML, "Homologous recombination deficiency(HRD)score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer", Clin Cancer Res, 22, pp.3764~3773 (2016)
15. Ali AA, "The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks", Nat Struct Mol Biol, 19, pp.685~692 (2012)
16. Murai J, "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors", Cancer Res, 72, pp.5588~5599 (2012)
17. Fong PC, "Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers", N Engl J Med, 361, pp.123~134 (2009)
18. Moore K, "Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer", N Engl J Med, 379, pp.2495~2505 (2018)
19. DiSilvestro P, "Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation : the SOLO1", GOG 3004 trial, 2023, pp.41, 609~617
20. Ledermann J, "Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer", N Engl J Med, 366, pp.1382~1392 (2012)
21. Tutt A, "Oral poly(ADP-ribose)polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer : a proof-of-concept trial", Lancet, 376, pp.235~244 (2010)
22. Mateo J, "DNA-repair defects and olaparib in metastatic prostate cancer", N Engl J Med, 373, pp.1697~1708 (2015)
23. Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
24. Koh G, "Mutational signatures : emerging concepts, caveats and clinical applications", Nat Rev Cancer, 21, pp.619~637 (2021)
25. Brady SW, "Therapeutic and prognostic insights from the analysis of cancer mutational signatures", Trends Genet, 38, pp.194~208 (2022)
26. Steele CD, "An overview of mutational and copy number signatures in human cancer", J Pathol, 257, pp.454~465 (2022)
27. Alexandrov LB, "The repertoire of mutational signatures in human cancer", Nature, 578, pp.94~101 (2020)
28. Degasperi A, "Substitution mutational signatures in whole-genome-sequenced cancers in the UK population", Science, 376, pp.science.abl9283~ (2022)
29. Senkin S, "Geographic variation of mutagenic exposures in kidney cancer genomes", Nature, 629, pp.910~918 (2024)
30. Cortes-Ciriano I, "Computational analysis of cancer genome sequencing data", Nat Rev Genet, 23, pp.298~314 (2022)
31. Kucab JE, "A compendium of mutational signatures of environmental agents", Cell, 177, pp.821~836 (2019)
32. Steele CD, "Signatures of copy number alterations in human cancer", Nature, 606, pp.984~991 (2022)
33. Macintyre G, "Copy number signatures and mutational processes in ovarian carcinoma", Nat Genet, 50, pp.1262~1270 (2018)
34. Drews RM, "A pan-cancer compendium of chromosomal instability", Nature, 606, pp.976~983 (2022)
35. Li Y, "Patterns of somatic structural variation in human cancer genomes", Nature, 578, pp.112~121 (2020)
36. Nik-Zainal S, "Landscape of somatic mutations in 560 breast cancer whole-genome sequences", Nature, 534, pp.47~54 (2016)
37. Alexandrov LB, "Deciphering signatures of mutational processes operative in human cancer", Cell Rep, 3, pp.246~259 (2013)
38. Polak P, "A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer", Nat Genet, 49, pp.1476~1486 (2017)
39. Zamborszky J, "Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions", Oncogene, 36, pp.746~755 (2017)
40. Poti A, "Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents", Genome Biol, 20, pp.240~ (2019)
41. Patterson-Fortin J, "Exploiting the microhomology-mediated end-joining pathway in cancer therapy", Cancer Res, 80, pp.4593~4600 (2020)
42. Gyure Z, "Spontaneous mutagenesis in human cells is controlled by REV1-polymerase zeta and PRIMPOL", Cell Rep, 42, pp.112887~ (2023)
43. Chen D, "BRCA1 deficiency specific base substitution mutagenesis is dependent on translesion synthesis and regulated by 53BP1", Nat Commun, 13, pp.226~ (2022)
44. Boot A, "Recurrent mutations in topoisomerase IIalpha cause a previously undescribed mutator phenotype in human cancers", Proc Natl Acad Sci U S A, 119, pp.e2114024119~ (2022)
45. Willis NA, "Mechanism of tandem duplication formation in BRCA1-mutant cells", Nature, 551, pp.590~595 (2017)
46. Menghi F, "The tandem duplicator phenotype as a distinct genomic configuration in cancer", Proc Natl Acad Sci U S A, 113, pp.E2373~E2382 (2016)
47. Degasperi A, "A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies", Nat Cancer, 1, pp.249~263 (2020)
48. Stark JM, "Genetic steps of mammalian homologous repair with distinct mutagenic consequences", Mol Cell Biol, 24, pp.9305~9316 (2004)
49. Setton J, "Long-molecule scars of backup DNA repair in BRCA1-and BRCA2-deficient cancers", Nature, 621, pp.129~137 (2023)
50. Davies H, "HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures", Nat Med, 23, pp.517~525 (2017)
51. Volkova NV, "Mutational signatures are jointly shaped by DNA damage and repair", Nat Commun, 11, pp.2169~ (2020)
52. Haradhvala NJ, "Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair", Nat Commun, 9, pp.1746~ (2018)
53. Wojtowicz D, "RepairSig : deconvolution of DNA damage and repair contributions to the mutational landscape of cancer", Cell Syst, 12, pp.994~1003 (2021)
54. Tomkova M, "Mutational signature distribution varies with DNA replication timing and strand asymmetry", Genome Biol, 19, pp.129~ (2018)
55. Vohringer H, "Learning mutational signatures and their multidimensional genomic properties with TensorSignatures", Nat Commun, 12, pp.3628~ (2021)
56. Jin H, "Accurate and sensitive mutational signature ana-lysis with MuSiCal", Nat Genet, 56, pp.541~552 (2024)
57. Gulhan DC, "Detecting the mutational signature of homologous recombination deficiency in clinical samples", Nat Genet, 51, pp.912~919 (2019)
58. Nguyen L, "Pan-cancer landscape of homologous recombination deficiency", Nat Commun, 11, pp.5584~ (2020)
59. Eeckhoutte A, "ShallowHRD : detection of homologous recombination deficiency from shallow whole genome sequencing", Bioinformatics, 36, pp.3888~3889 (2020)
60. Hoppe MM, "Biomarkers for homologous recombination deficiency in cancer", J Natl Cancer Inst, 110, pp.704~713 (2018)
61. de Bono J, "Olaparib for metastatic castration-resistant prostate cancer", N Engl J Med, 382, pp.2091~2102 (2020)
62. Hodgson DR, "Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes", Br J Cancer, 119, pp.1401~1409 (2018)
63. Pujade-Lauraine E, "Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1", ENGOT-ov25 trial, 2023, pp.7, e2200258~
64. Batalini F, "Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers", Clin Cancer Res, 28, pp.4714~4723 (2022)
65. Farkkila A, "Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer", Nat Commun, 11, pp.1459~ (2020)
66. Callens C, "Shallow whole genome sequencing approach to detect homologous recombination deficiency in the PAOLA-1", ENGOT-OV25 phase-III trial, 2023, pp.42, 3556~3563
67. Ray-Coquard I, "Olaparib plus bevacizumab as first-line maintenance in ovarian cancer", N Engl J Med, 381, pp.2416~2428 (2019)
68. Gonzalez-Martin A, "Niraparib in patients with newly diagnosed advanced ovarian cancer", N Engl J Med, 381, pp.2391~2402 (2019)
69. Pujade-Lauraine E, "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1", 2 mutation(SOLO2, Lancet Oncol, pp.2017, 18[DOI]
70. Mirza MR, "Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer", N Engl J Med, 375, pp.2154~2164 (2016)
71. Coleman RL, "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.1949~1961 (2017)
72. Tutt AN, "Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer", N Engl J Med, 384, pp.2394~2405 (2021)
73. Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
74. Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
75. Abida W, "Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration", J Clin Oncol, 38, pp.3763~3772 (2020)
76. Agarwal N, "Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer(TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial", Lancet, 402, pp.291~303 (2023)
77. Clarke NW, "Abiraterone and olaparib for metastatic castration-resistant prostate cancer", NEJM Evid, 1, pp.EVIDoa2200043~ (2022)
78. Golan T, "Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer", N Engl J Med, 381, pp.317~327 (2019)
79. Sboner A, "The real cost of sequencing: higher than you think!", Genome Biol, 12, pp.125~ (2011)
80. Kinnersley B, "Analysis of 10, 478 cancer genomes identifies candidate driver genes and opportunities for precision oncology", Nat Genet, 56, pp.1868~1877 (2024)
81. Sosinsky A, "Insights for precision oncology from the integration of genomic and clinical data of 13, 880 tumors from the 100, 000 Genomes Cancer Programme", Nat Med, 30, pp.279~289 (2024)
82. Shin HT, "Prevalence and detection of low-allele-fraction variants in clinical cancer samples", Nat Commun, 8, pp.1377~ (2017)
83. Haile S, "Sources of erroneous sequences and artifact chimeric reads in next generation sequencing of genomic DNA from formalin-fixed paraffin-embedded samples", Nucleic Acids Res, 47, pp.e12~ (2019)
84. Tobalina L, "A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance", Ann Oncol, 32, pp.103~112 (2021)
85. Lin KK, "BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma", Cancer Discov, 9, pp.210~219 (2019)
86. Harvey-Jones E, "Longitudinal profiling identifies co-occurring BRCA1", 2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer, 2024, pp.35, 364~380
87. Dias MP, "Understanding and overcoming resistance to PARP inhibitors in cancer therapy", Nat Rev Clin Oncol, 18, pp.773~791 (2021)
88. Li H, "PARP inhibitor resistance : the underlying mechanisms and clinical implications", Mol Cancer, 19, pp.107~ (2020)
89. Gupta N, "Cell cycle checkpoints and beyond : exploiting the ATR", CHK1, Pharmacol Res, pp.2022, 178[DOI]
90. Kim YN, "Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer", Clin Cancer Res, 29, pp.2725~2734 (2023)
91. Jacobson DH, "Multi-scale characterisation of homologous recombination deficiency in breast cancer", Genome Med, 15, pp.90~ (2023)
92. Muyas F, "De novo detection of somatic mutations in high-throughput single-cell profiling data sets", Nat Biotechnol, 42, pp.758~767 (2024)
93. Gao T, "Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes", Nat Biotechnol, 41, pp.417~426 (2023)
94. Baysoy A, "The technological landscape and applications of single-cell multi-omics", Nat Rev Mol Cell Biol, 24, pp.695~713 (2023)

관련 논문AI추천